Hemophagocytic lymphohistiocytosis: Pathogenesis, diagnosis, and management

Pediatrics International

Volumn 58, Issue 9, 2016, Pages 817-825

  Morimoto, Akira ^a   Nakazawa, Yozo ^b   Ishii, Eiichi ^c  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

cytotoxic T lymphocyte; Epstein Barr virus; Ferritin; perforin; 2 microglobulin

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; DEXAMETHASONE; IMMUNOGLOBULIN; METHYLPREDNISOLONE; CYTOKINE;

CAUSAL ATTRIBUTION; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DISEASE CLASSIFICATION; DISEASE SURVEILLANCE; DRUG EFFECT; EPSTEIN BARR VIRUS; HEMOPHAGOCYTIC SYNDROME; HUMAN; IMMUNOPATHOGENESIS; MOLECULAR DIAGNOSIS; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT PLANNING; AUTOIMMUNITY; DISEASE MANAGEMENT; IMMUNOLOGY; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; METABOLISM;

AUTOIMMUNITY; CYTOKINES; DISEASE MANAGEMENT; HUMANS; KILLER CELLS, NATURAL; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC;

EID: 84988931214     PISSN: 13288067     EISSN: 1442200X     Source Type: Journal    
DOI: 10.1111/ped.13064     Document Type: Review

References (67)

1. Janka GE, Lehmberg K. Hemophagocytic lymphohistiocytosis: pathogenesis and treatment. Hematol. Am. Soc. Hematol. Educ. Program 2013; 2013: 605–11.
2. Henter JI, Samuelsson-Horne A, Aricò M et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood 2002; 100: 2367–73.
3. Ishii E, Ohga S, Imashuku S et al. Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. Int. J. Hematol. 2007; 86: 58–65.
4. Ueda I, Kurokawa Y, Koike K et al. Late-onset cases of familial hemophagocytic lymphohistiocytosis with missense perforin gene mutations. Am. J. Hematol. 2007; 82: 427–32.
5. Nagafuji K, Nonami A, Kumano T et al. Perforin gene mutations in adult-onset hemophagocytic lymphohistiocytosis. Haematologica 2007; 92: 978–81.
6. Nagai K, Yamamoto K, Fujiwara H et al. Subtypes of familial hemophagocytic lymphohistiocytosis in Japan based on genetic and functional analyses of cytotoxic T lymphocytes. PLoS ONE 2010; 5: e14173.
7. Ueda I, Morimoto A, Inaba T et al. Characteristic perforin gene mutations of haemophagocytic lymphohistiocytosis patients in Japan. Br. J. Haematol. 2003; 121: 503–10.
8. Yamamoto K, Ishii E, Sako M et al. Identification of novel MUNC13-4 mutations in familial haemophagocytic lymphohistiocytosis and functional analysis of MUNC13-4-deficient cytotoxic T lymphocytes. J. Med. Genet. 2004; 41: 763–7.
9. Bryceson YT, Rudd E, Zheng C et al. Defective cytotoxic lymphocyte degranulation in syntaxin-11 deficient familial hemophagocytic lymphohistiocytosis 4 (FHL4) patients. Blood 2007; 110: 1906–15.
10. zur SU, Rohr J, Seifert W et al. Familial hemophagocytic lymphohistiocytosis type 5 (FHL-5) is caused by mutations in Munc18-2 and impaired binding to syntaxin 11. Am. J. Hum. Genet. 2009; 85: 482–92.
11. Spessott WA, Sanmillan ML, McCormick ME et al. Hemophagocytic lymphohistiocytosis caused by dominant-negative mutations in STXBP2 that inhibit SNARE-mediated membrane fusion. Blood 2015; 125: 1566–77.
12. Zur SU, Beutel K, Kolberg S et al. Mutation spectrum in children with primary hemophagocytic lymphohistiocytosis: molecular and functional analyses of PRF1, UNC13D, STX11, and RAB27A. Hum. Mutat. 2006; 27: 62–8.
13. Nagai K, Ochi F, Terui K et al. Clinical characteristics and outcomes of Chédiak-Higashi syndrome: a nationwide survey of Japan. Pediatr. Blood Cancer 2013; 60: 1582–6.
14. Enders A, Zieger B, Schwarz K et al. Lethal hemophagocytic lymphohistiocytosis in Hermansky-Pudlak syndrome type II. Blood 2006; 108: 81–7.
15. Kanegane H, Yang X, Zhao M et al. Clinical features and outcome of X-linked lymphoproliferative syndrome type 1 (SAP deficiency) in Japan identified by the combination of flow cytometric assay and genetic analysis. Pediatr. Allergy Immunol. 2012; 23: 488–93.
16. Yang X, Kanegane H, Nishida N et al. Clinical and genetic characteristics of XIAP deficiency in Japan. J. Clin. Immunol. 2012; 32: 411–20.
17. Huck K, Feyen O, Niehues T et al. Girls homozygous for an IL-2-inducible T cell kinase mutation that leads to protein deficiency develop fatal EBV-associated lymphoproliferation. J. Clin. Invest. 2009; 119: 1350–8.
18. Alkhairy OK, Perez-Becker R, Driessen GJ et al. Novel mutations in TNFRSF7/CD27: clinical, immunologic, and genetic characterization of human CD27 deficiency. J. Allergy Clin. Immunol. 2015; 136: 703–12.
19. Takahashi N, Miura I, Chubachi A, Miura AB, Nakamura S. A clinicopathological study of 20 patients with T/natural killer (NK)-cell lymphoma-associated hemophagocytic syndrome with special reference to nasal and nasal-type NK/T-cell lymphoma. Int. J. Hematol. 2001; 74: 303–8.
20. Lehmberg K, Sprekels B, Nichols KE et al. Malignancy-associated haemophagocytic lymphohistiocytosis in children and adolescents. Br. J. Haematol. 2015; 170: 539–49.
21. Favara BE, Jaffe R, Egeler RM. Macrophage activation and hemophagocytic syndrome in Langerhans cell histiocytosis: report of 30 cases. Pediatr. Dev. Pathol. 2002; 5: 130–40.
22. Ravelli A, Davì S, Minoia F, Martini A, Cron RQ. Macrophage activation syndrome. Hematol. Oncol. Clin. North Am. 2015; 29: 927–41.
23. Asano T, Kogawa K, Morimoto A et al. Hemophagocytic lymphohistiocytosis after hematopoietic stem cell transplantation in children: a nationwide survey in Japan. Pediatr. Blood Cancer 2012; 59: 110–4.
24. Gauchan D, Shaaban H, Parikh N, Chang NL, Altheeb Z, Maroules M. Severe hemophagocytic lymphohistiocytosis as a complication of drug-induced hypersensitivity syndrome. Int. J. Crit. Illn. Inj. Sci. 2015; 5: 60–1.
25. Fujiwara F, Hibi S, Imashuku S. Hypercytokinemia in hemophagocytic syndrome. Am. J. Pediatr. Hematol. Oncol. 1993; 15: 92–8.
26. Takada H, Nomura A, Ohga S, Hara T. Interleukin-18 in hemophagocytic lymphohistiocytosis. Leuk. Lymphoma 2001; 42: 21–8.
27. Eskander ED, Harvey HA, Givant E, Lipton A. Phase I study combining tumor necrosis factor with interferon-alpha and interleukin-2. Am. J. Clin. Oncol. 1997; 20: 511–4.
28. Jordan MB, Hildeman D, Kappler J, Marrack P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood 2004; 104: 735–43.
29. Su MW, Pyarajan S, Chang JH et al. Fratricide of CD8+ cytotoxic T lymphocytes is dependent on cellular activation and perforin-mediated killing. Eur. J. Immunol. 2004; 34: 2459–70.
30. Terrell CE, Jordan MB. Perforin deficiency impairs a critical immunoregulatory loop involving murine CD8(+) T cells and dendritic cells. Blood 2013; 121: 5184–91.
31. Toga A, Wada T, Sakakibara Y et al. Clinical significance of cloned expansion and CD5 down-regulation in Epstein-Barr Virus (EBV)-infected CD8+ T lymphocytes in EBV-associated hemophagocytic lymphohistiocytosis. J. Infect. Dis. 2010; 201: 1923–32.
32. Hatta K, Morimoto A, Ishii E et al. Association of transforming growth factor-beta1 gene polymorphism in the development of Epstein-Barr virus-related hematologic diseases. Haematologica 2007; 92: 1470–4.
33. Yanagimachi M, Goto H, Miyamae T et al. Association of IRF5 polymorphisms with susceptibility to hemophagocytic lymphohistiocytosis in children. J. Clin. Immunol. 2011; 31: 946–51.
34. Fujiwara S, Kimura H, Imadome K et al. Current research on chronic active Epstein-Barr virus infection in Japan. Pediatr. Int. 2014; 56: 159–66.
35. Cannella S, Santoro A, Bruno G et al. Germline mutations of the perforin gene are a frequent occurrence in childhood anaplastic large cell lymphoma. Cancer 2007; 109: 2566–71.
36. Chang TY, Jaffray J, Woda B, Newburger PE, Usmani GN. Hemophagocytic lymphohistiocytosis with MUNC13-4 gene mutation or reduced natural killer cell function prior to onset of childhood leukemia. Pediatr. Blood Cancer 2011; 56: 856–8.
37. Bleesing J, Prada A, Siegel DM et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum. 2007; 56: 965–71.
38. Henter JI, Horne A, Aricó M et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer 2007; 48: 124–31.
39. Ravelli A, Minoia F, Davì S et al. 2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol. 2016; 68: 566–76.
40. Parodi A, Davì S, Pringe AB et al. Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients. Arthritis Rheum. 2009; 60: 3388–99.
41. Esumi N, Ikushima S, Hibi S, Todo S, Imashuku S. High serum ferritin level as a marker of malignant histiocytosis and virus-associated hemophagocytic syndrome. Cancer 1988; 61: 2071–6.
42. Hibi S, Ikushima S, Fujiwara F et al. Serum and urine beta-2-microglobulin in hemophagocytic syndrome. Cancer 1995; 75: 1700–5.
43. Nishida M, Kawakatsu H, Komatsu H et al. Values for urinary beta 2-microglobulin and N-acetyl-beta-D-glucosaminidase in normal healthy infants. Acta Paediatr. Jpn. 1998; 40: 424–6.
44. Gotoh Y, Okamoto Y, Uemura O et al. Determination of age-related changes in human soluble interleukin 2 receptor in body fluids of normal subjects as a control value against disease states. Clin. Chim. Acta 1999; 289: 89–97.
45. Ishii E, Ueda I, Shirakawa R et al. Genetic subtypes of familial hemophagocytic lymphohistiocytosis: correlations with clinical features and cytotoxic T lymphocyte/natural killer cell functions. Blood 2005; 105: 3442–8.
46. Chong KW, Lee JH, Choong CT et al. Hemophagocytic lymphohistiocytosis with isolated central nervous system reactivation and optic nerve involvement. J. Child Neurol. 2012; 27: 1336–9.
47. Murata Y, Yasumi T, Shirakawa R et al. Rapid diagnosis of FHL3 by flow cytometric detection of intraplatelet Munc13-4 protein. Blood 2011; 118: 1225–30.
48. Bryceson YT, Pende D, Maul-Pavicic A et al. A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes. Blood 2012; 119: 2754–63.
49. Yang X, Miyawaki T, Kanegane H. SAP and XIAP deficiency in hemophagocytic lymphohistiocytosis. Pediatr. Int. 2012; 54: 447–54.
50. Horne A, Trottestam H, Aricò M et al. Frequency and spectrum of central nervous system involvement in 193 children with haemophagocytic lymphohistiocytosis. Br. J. Haematol. 2008; 140: 327–35.
51. Sawada A, Ohga S, Ishii E et al. Feasibility of reduced-intensity conditioning followed by unrelated cord blood transplantation for primary hemophagocytic lymphohistiocytosis: a nationwide retrospective analysis in Japan. Int. J. Hematol. 2013; 98: 223–30.
52. Jordan M, Locatelli F, Allen C et al. A novel targeted approach to the treatment of hemophagocytic lymphohistiocytosis (HLH) with an anti-interferon gamma (IFN?) monoclonal antibody (mAb), NI-0501: first results from a pilot phase 2 study in children with primary HLH. Blood 2015; 126: LBA-3 [Abstract].
53. Imashuku S. Clinical features and treatment strategies of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Crit. Rev. Oncol. Hematol. 2002; 44: 259–72.
54. Shiraishi A, Ohga S, Doi T et al. Treatment choice of immunotherapy or further chemotherapy for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer 2012; 59: 265–70.
55. Kikuta H, Sakiyama Y. Etoposide (VP-16) inhibits Epstein-Barr virus determined nuclear antigen (EBNA) synthesis. Br. J. Haematol. 1995; 90: 971–3.
56. Ohga S, Kudo K, Ishii E et al. Hematopoietic stem cell transplantation for familial hemophagocytic lymphohistiocytosis and Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in Japan. Pediatr. Blood Cancer 2010; 54: 299–306.
57. Kogawa K, Sato H, Asano T et al. Prognostic factors of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children: report of the Japan Histiocytosis Study Group. Pediatr. Blood Cancer 2014; 61: 1257–62.
58. Chellapandian D, Das R, Zelley K et al. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens. Br. J. Haematol. 2013; 162: 376–82.
59. Imashuku S, Kudo N, Kubo K, Yachie A. Are regimens containing rituximab effective in the initial treatment of Epstein-Barr virus-positive natural killer cell lymphoproliferative disease-associated hemophagocytic lymphohistiocytosis? Int. J. Hematol. 2013; 98: 375–7.
60. Bond J, Shahdadpuri R, McMahon C, O'marcaigh A, Cotter M, Smith O. Successful treatment of acute Epstein-Barr virus infection associated with X-linked lymphoproliferative disorder with rituximab. Pediatr. Blood Cancer 2007; 49: 761–2.
61. Sato E, Ohga S, Kuroda H et al. Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease in Japan. Am. J. Hematol. 2008; 83: 721–7.
62. Suzuki N, Morimoto A, Ohga S, Kudo K, Ishida Y, Ishii E. Characteristics of hemophagocytic lymphohistiocytosis in neonates: a nationwide survey in Japan. J. Pediatr. 2009; 155: 235–8.
63. Pinninti SG, Kimberlin DW. Management of neonatal herpes simplex virus infection and exposure. Arch. Dis. Child. Fetal Neonatal Ed. 2014; 99: F240–4.
64. Yu JT, Wang CY, Yang Y et al. Lymphoma-associated hemophagocytic lymphohistiocytosis: experience in adults from a single institution. Ann. Hematol. 2013; 92: 1529–36.
65. Minoia F, Davì S, Horne A et al. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheumatol. 2014; 66: 3160–9.
66. Koyama M, Sawada A, Yasui M, Inoue M, Kawa K. Encouraging results of low-dose etoposide in the treatment of early-onset hemophagocytic syndrome following allogeneic hematopoietic stem cell transplantation. Int. J. Hematol. 2007; 86: 466–7.
67. Prais D, Straussberg R, Amir J, Nussinovitch M, Harel L. Treatment of anticonvulsant hypersensitivity syndrome with intravenous immunoglobulins and corticosteroids. J. Child Neurol. 2006; 21: 380–4.